Skip to main content
. Author manuscript; available in PMC: 2020 May 9.
Published in final edited form as: Neuropharmacology. 2019 Jul 1;160:107690. doi: 10.1016/j.neuropharm.2019.107690

Fig. 2.

Fig. 2.

Dose-response curves illustrating the reduction in tumor-evoked mechanical hyperalgesia following systemic administration of MMG22 (s.c., i.m., and oral) on different post-implantation days (PID). Data in upper panels show mean (± SEM) % maximum possible effect. A) Antinociception s.c. administration of MMG22 increased from PID4–17. The increase in potency occurred at all subsequent time points tested. B) Reduction in mechanical hyperalgesia on different PIDs following i.m. administration of MMG22. C) Reduction in mechanical hyperalgesia on different PIDs following oral administration of MMG22. The X-axis scale in A differs from those in B and C because of the greater number of doses used. Lower panels show mean paw withdrawal frequencies that correspond to the MPE% in the panels above.